SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

18 May 2023 Evaluate
The sales slipped to Rs. 7854.22 millions for the March 2023 quarter as against Rs. 11030.14 millions during the year-ago period.A big decline of -72.30% was reported for the quarter ended March 2023 to Rs. 792.06  millions from Rs. 2859.76 millions of corresponding previous quarter.The company reported a degrowth in operating Profit to 2080.92 millions from 4136.65 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 7854.22 11030.14 -28.79 36165.28 44007.08 -17.82 36165.28 44007.08 -17.82
Other Income 389.39 652.34 -40.31 2404.64 2239.40 7.38 2404.64 2239.40 7.38
PBIDT 2080.92 4136.65 -49.70 12590.13 17345.79 -27.42 12590.13 17345.79 -27.42
Interest 21.81 20.32 7.33 74.14 52.40 41.49 74.14 52.40 41.49
PBDT 1494.50 4116.33 -63.69 11951.38 17293.39 -30.89 11951.38 17293.39 -30.89
Depreciation 375.42 310.75 20.81 1467.36 1102.96 33.04 1467.36 1102.96 33.04
PBT 1119.08 3805.58 -70.59 10484.02 16190.43 -35.25 10484.02 16190.43 -35.25
TAX 327.02 945.82 -65.42 2725.76 4068.88 -33.01 2725.76 4068.88 -33.01
Deferred Tax -104.98 93.23 -212.60 -27.99 140.08 -119.98 -27.99 140.08 -119.98
PAT 792.06 2859.76 -72.30 7758.26 12121.55 -36.00 7758.26 12121.55 -36.00
Equity 164.70 164.30 0.24 164.70 164.30 0.24 164.70 164.30 0.24
PBIDTM(%) 26.49 37.50 -29.35 34.81 39.42 -11.68 34.81 39.42 -11.68

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×